You just read:

Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II

News provided by

Sangamo Therapeutics, Inc.

Jul 13, 2017, 16:01 ET